Ingrid Garberis

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele, Élise Deluche, Amélie Lusque et al. · Nature Medicine · 2023 · 370 citations · Full text

Medicine, Oncology, Pharmacology +17

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Fernanda Mosele, Bojana Stefanovska, Amélie Lusque et al. · Annals of Oncology · 2020 · 320 citations · Full text

Medicine, Cancer Biology, Oncology +14

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Thomas Bachelot, Thomas Filleron, Ivan Bièche et al. · Nature Medicine · 2021 · 158 citations

Medicine, Oncology, Pharmacology +9

Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status

Dan Ou, Pierre Blanchard, Silvia Rosellini et al. · Oral Oncology · 2017 · 98 citations · Full text

Medicine, Oncology, Radiology +16

LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

M.F. Mosele, Amélie Lusque, Véronique Dièras et al. · Annals of Oncology · 2022 · 48 citations

Medicine, Oncology, Pharmacology +17